|
시장보고서
상품코드
2131346
비발리루딘 의약품 시장 규모, 점유율, 성장 분석 : 제품 유형별, 제형별, 적응증별, 최종사용자별, 유통 채널별, 지역별 - 산업 예측(2026-2033년)Bivalirudin Drug Market Size, Share, and Growth Analysis, By Product Type (Branded Bivalirudin, Generic Bivalirudin), By Dosage Form, By Indication, By End User, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 비발리루딘 의약품 시장 규모는 2024년에 8억 2,000만 달러로 평가되며, 2025년 8억 6,428만 달러에서 2033년까지 13억 1,638만 달러로 확대될 전망이며, 예측 기간(2026-2033년) 동안 CAGR 5.4%로 성장할 것으로 전망됩니다.
세계 비발리루딘 시장은 주로 경피적 관상동맥 중재술(PCI)에 사용되는 이 직접 트롬빈 억제제의 개발, 제조 및 유통을 특징으로 합니다. 이 약물의 주요 장점은 헤파린에 비해 출혈 위험을 최소화할 수 있다는 점에 있으며, 이로 인해 병원 약품 목록에 채택되는 사례가 증가하고 있습니다. 임상 연구를 통해 뛰어난 안전성 프로파일이 입증됨에 따라 보험 적용이 확대되고, 카테터실에서의 사용이 늘어나면서 시장이 발전해 왔습니다. 성장의 요인으로는 급성 관상동맥 증후군 및 복잡하고 고위험 시술에서 비발리루딘의 적응증 확대가 꼽힙니다. 이에 따라 시술 중 사망률을 낮춘다는 이 약물의 매력이 더욱 부각되고 있습니다. 또한, 아시아태평양에서 심혈관질환 유병률이 증가하는 가운데, 병원들은 국제적인 안전 기준을 준수하기 위해 비발리루딘의 도입을 추진하고 있습니다. 이러한 동향이 수요를 촉진하고, 투자를 유치하며, 제제 혁신을 주도함으로써 국제적인 시장 성장을 가속화하고 있습니다.
세계 비발리루딘 의약품 시장의 성장요인
세계 비발리루딘 의약품 시장의 주요 성장 요인 중 하나는 특히 고령화 사회에서 심혈관질환 유병률이 증가하고 있다는 점입니다. 급성 관상동맥 증후군이나 경피적 관상동맥 중재술(PCI)과 같은 질환이 더욱 보편화됨에 따라, 비발리루딘과 같은 효과적인 항응고제에 대한 수요가 높아지고 있습니다. 우수한 안전성 프로파일과 시술 중 합병증을 줄이는 효과와 같은 장점 덕분에, 비발리루딘은 현대 치료 프로토콜에서 필수적인 요소로 자리 잡았습니다. 또한, 의료 기술의 지속적인 발전과 의료 종사자들 사이에서 비발리루딘의 이점에 대한 인식이 높아짐에 따라 시장 성장이 더욱 가속화되고 있으며, 항응고 요법에서 우선적인 선택지로 자리매김하고 있습니다.
세계 비발리루딘 의약품 시장의 제약요인
세계 비발리루딘 의약품 시장의 주요 제약요인 중 하나는 동등한 효능을 가지면서도 더 우수한 안전성 프로파일을 갖춘 대체 항응고 요법의 등장입니다. 직접 경구용 항응고제(DOAC) 및 기타 신약의 등장으로 경쟁이 심화되어 비발리루딘의 시장 점유율을 제한할 가능성이 있습니다. 또한, 비발리루딘의 높은 비용에 대한 우려와 의료비 절감 압력이 맞물려 다양한 의료 현장에서의 도입을 저해할 수 있습니다. 또한, 비발리루딘의 투여는 복잡하고, 많은 경우 신중한 모니터링이나 용량 조정이 필요하기 때문에 의료진이 더 간편한 대체 약물을 선택하는 것을 주저하게 만들어 시장 성장을 더욱 제약할 가능성이 있습니다.
세계 비발리루딘 의약품 시장 동향
세계 비발리루딘 시장에서는 심혈관 의료 분야에서의 적응증 확대라는 뚜렷한 동향이 나타나고 있습니다. 의료 종사자들이 복잡한 구조적 심장 중재술이나 오프펌프 관상동맥 우회술을 포함한 다양한 시술에서 비발리루딘의 이점을 점점 더 인식함에 따라, 이 약물의 채택은 현저히 증가하고 있습니다. 이러한 변화는 비발리루딘의 유효성과 낮은 출혈 위험을 보여주는 설득력 있는 증거에 힘입어, 지침 위원회에서 고위험 환자에 대한 사용을 권장하는 단계에 이르렀습니다. 그 결과, 각 병원에서는 치료 프로토콜 재검토가 진행되고 있으며, 이는 수요 증가를 촉진하는 동시에 제조사의 교육 및 지원 활동 강화를 뒷받침하여 궁극적으로 전 세계 시장 성장을 촉진하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 비발리루딘 의약품 시장 규모 : 제품 유형별
세계의 비발리루딘 의약품 시장 규모 : 제형별
세계의 비발리루딘 의약품 시장 규모 : 적응증별
세계의 비발리루딘 의약품 시장 규모 : 최종사용자별
세계의 비발리루딘 의약품 시장 규모 : 유통 채널별
세계의 비발리루딘 의약품 시장 규모 : 지역별
세계의 비발리루딘 의약품 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.10.01Global Bivalirudin Drug Market size was valued at USD 820.0 Million in 2024 and is poised to grow from USD 864.28 Million in 2025 to USD 1316.38 Million by 2033, growing at a CAGR of 5.4% during the forecast period (2026-2033).
The global bivalirudin market is characterized by the development, production, and distribution of this direct thrombin inhibitor, primarily used in percutaneous coronary interventions. Its key advantage lies in its ability to minimize bleeding risks compared to heparin, leading to increased adoption in hospital formularies. The market has evolved as clinical studies illustrated its superior safety profile, prompting insurance reimbursements and broader utilization in catheter labs. Growth drivers include expanding indications for bivalirudin in acute coronary syndrome and complex high-risk procedures, which enhance its appeal for reducing procedural mortality. Additionally, as cardiovascular disease rates rise in the Asia-Pacific region, hospitals are moving towards bivalirudin to adhere to international safety standards. These trends are fostering demand, attracting investments, and driving innovation in formulations, thus accelerating market growth internationally.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Bivalirudin Drug market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Bivalirudin Drug Market Segments Analysis
Global bivalirudin drug market is segmented by product type, dosage form, indication, end user, distribution channel and region. Based on product type, the market is segmented into Branded Bivalirudin and Generic Bivalirudin. Based on dosage form, the market is segmented into Lyophilized Powder and Injectable Solution. Based on indication, the market is segmented into Percutaneous Coronary Intervention (PCI), Acute Coronary Syndrome (ACS) and Others. Based on end user, the market is segmented into Hospitals, Cardiac Centers, Ambulatory Surgical Centers and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Bivalirudin Drug Market
One key market driver for the global Bivalirudin drug market is the rising prevalence of cardiovascular diseases, particularly in an aging population. As conditions such as acute coronary syndrome and percutaneous coronary interventions become more common, the demand for effective anticoagulants like Bivalirudin is increasing. Its benefits, including a favorable safety profile and efficacy in reducing complications during procedures, make it a critical component in modern therapeutic protocols. Additionally, ongoing advancements in medical technology and increasing awareness among healthcare professionals about the advantages of Bivalirudin are further propelling market growth, positioning it as a preferred choice in anticoagulation therapy.
Restraints in the Global Bivalirudin Drug Market
One key market restraint for the global Bivalirudin drug market is the emergence of alternative anticoagulant therapies that offer comparable efficacy with improved safety profiles. The availability of direct oral anticoagulants (DOACs) and other novel agents has increased competition, potentially limiting Bivalirudin's market share. Additionally, concerns regarding the high cost of Bivalirudin, coupled with the pressure to reduce healthcare spending, can hinder its adoption in various healthcare settings. The complexity of administering Bivalirudin, often requiring careful monitoring and dose adjustment, may also deter healthcare providers from choosing it over simpler alternatives, further constraining market growth.
Market Trends of the Global Bivalirudin Drug Market
The global bivalirudin drug market is experiencing a notable trend towards expanding its applications within cardiovascular medicine. As healthcare professionals increasingly recognize the benefits of bivalirudin for various procedures, including complex structural heart interventions and off-pump coronary artery bypass grafting, the drug's adoption is rising significantly. This shift is fueled by compelling evidence showcasing its efficacy and lower bleeding risk, leading to recommendations from guideline committees for its use in high-risk patients. Consequently, hospitals are revising their treatment protocols, which is prompting increased demand and motivating manufacturers to enhance education and support initiatives, thereby stimulating market growth globally.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Bivalirudin Drug Market Size by Product Type & CAGR (2026-2033)
- Market Overview
- Branded Bivalirudin
- Generic Bivalirudin
Global Bivalirudin Drug Market Size by Dosage Form & CAGR (2026-2033)
- Market Overview
- Lyophilized Powder
- Injectable Solution
Global Bivalirudin Drug Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Percutaneous Coronary Intervention (PCI)
- Acute Coronary Syndrome (ACS)
- Others
Global Bivalirudin Drug Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Cardiac Centers
- Ambulatory Surgical Centers
- Others
Global Bivalirudin Drug Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Bivalirudin Drug Market Size by Region & CAGR (2026-2033)
- Market Overview
- North America
- Europe
- Asia-Pacific
- Rest of the World
Global Bivalirudin Drug Market Size & CAGR (2026-2033)
- North America (Product Type, Dosage Form, Indication, End User, Distribution Channel, Region)
- US
- Canada
- Europe (Product Type, Dosage Form, Indication, End User, Distribution Channel, Region)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Product Type, Dosage Form, Indication, End User, Distribution Channel, Region)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Product Type, Dosage Form, Indication, End User, Distribution Channel, Region)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Product Type, Dosage Form, Indication, End User, Distribution Channel, Region)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fresenius Kabi AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz Group AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Baxter International Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amneal Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Lifesciences Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gland Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Intas Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aspen Pharmacare Holdings Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Xellia Pharmaceuticals A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hospira
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- B. Braun SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ferrer Internacional S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
(주말 및 공휴일 제외)
